PepCF
$WVE Trading near net cash (~$2.20) means Wall St is assigning $0 value to the entire RNA platform. Pure nonsense given $19 offering & RA Cap buying at $6.
Key catalysts ahead:
🔹 WVE-006 (AATD): Patient MAD proof-of-concept data
🔹 WVE-007 (Obesity): Ph 1/2 clinical readout
🔹 WVE-N531 (DMD): Exon skipping follow-up
🔹 WVE-003 (HD): Post-dose selection advances
🔹 WVE-008 (Stargardt): RNA editing advances in ABCA4
Nothing left to lose at these levels.
9
